drugset / Trial / NCT05191225
Ultrafast Truxima Infusion in Non-Hodgkin's Lymphoma: Txagorapid Study
Non-randomizedSequentialOpen-labelTreatment
Summary
The objective of this pilot study is therefore to assess the safety of Truxima ultrafast infusion within 30 minutes in patients with non-Hodgkin's lymphoma.
Timeline
- Start
- 2021-09-28
- Primary completion
- 2022-03
- Completion
- 2022-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rituximab | Monoclonal antibody | 375 mg/m2 | Intravenous |